Latest News & Features
Americas
Speakers from Mammoth Biosciences, Cargo Therapeutics, Star Therapeutics, and Greenberg Traurig, discuss academia and industry, technology transfer, and leveraging research for commercialisation. 19 December 2024
Americas
Speakers from Akin, Bristol Myers Squibb, Gilead Sciences, and Pfizer discuss how AI accelerates drug discovery, from target identification to predictive modelling, reducing costs and enhancing therapeutic outcomes. 19 December 2024
Americas
Pair of generic drug makers challenged validity of patent on priority, novelty and inventive step | EPO found the patent did not introduce any new matter not originally disclosed in the pharma company’s application. 19 December 2024
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg. 19 December 2024
Americas
In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step. 18 December 2024
Americas
Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights. 18 December 2024
Americas
LSIPR’s key event series to host its inaugural ceremony next year in Boston | Spotlight on top innovators and firms in life sciences IP | Gala to honour contributions across 21 categories with 15 judges. 17 December 2024
Americas
Regeneron inks deal over suit concerning a protein for testing COVID-19 treatments | BioNTech aims to resolve university dispute over patented tech used in the Comirnaty vaccine. 17 December 2024
Americas
A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win. 16 December 2024
Americas
Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation. 15 December 2024